Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

By sjmartinez • December 30, 2025

Bloomfield GS, Watanabe M, McCallum S, Aberg JA, Awwad A, Campbell TB, Cespedes MS, Chu SM, Currier JS, Diggs MR, Sponseller CA, Fichtenbaum CJ, Lu MT, Malvestutto CD, Pierone G, Rhame F, Tuan J, Zhao S, Zanni MV, Grinspoon SK, Ribaudo HJ, Douglas PS. Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Circ Heart Fail. 2025 Dec 29:e013382. doi: 10.1161/CIRCHEARTFAILURE.125.013382. Epub ahead of print. PMID: 41457980.

Tags: cardiovascular disease, cell count, heart failure, Hypertension, Infectious Diseases, Obesity, Publications

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

The Cost and Intermediate Cost-Effectiveness of a Randomized Control Trial Delivering U=U Messaging to Increase HIV Testing Among South African Men

Smith PJ, Davey DJ, Schmucker L, Bekker LG, Medina-Marino A, Thirumurthy H, Buttenheim AM, Meyer-Rath G. The Cost and Intermediate Cost-Effectiveness of a Randomized Control[...]

Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges

Murdande S, Mishra S, Munoz A, Fox K, D'Assumpcao C. Mpox in advanced AIDS with concurrent opportunistic infections: periprocedural management challenges. Infect Prev Pract. 2026[...]